ICER releases draft evidence report on novel agents to prevent chemotherapy-induced neutropenia


25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 February 2022.

The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of plinabulin (BeyondSpring Pharmaceuticals) and trilaciclib (Cosela, G1 Therapeutics) for the prevention of chemotherapy-induced neutropenia and other myelosuppressive effects.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder